UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 8, 2021
MONOPAR
THERAPEUTICS INC.
|
(Exact name of
registrant as specified in its charter)
|
Deleware
|
|
001-39070
|
|
32-0463781
|
(State or other
jurisdiction of incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
1000 Skokie Blvd.,
Suite 350, Wilmette, IL
|
|
|
|
60091
|
(Address of
principal executive offices)
|
|
|
|
(Zip
Code)
|
|
|
|
|
|
|
|
(847)
388-0349
|
|
|
|
|
Registrant’s
telephone number, including area code
|
|
|
|
|
|
|
|
|
|
N/A
|
|
|
|
|
(Former name or
former address, if changed since last
report)
|
|
|
|
|
|
|
|
|
|
Securities
registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which
registered
|
Common
Stock, $0.001 par value
|
|
MNPR
|
|
The
Nasdaq Stock Market LLC (Nasdaq Capital Market)
|
|
|
|
|
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§ 240.12b-2 of this chapter).
Emerging growth
company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☒
Item
7.01 Regulation FD Disclosure
On
December 8, 2021, Monopar Therapeutics Inc. issued a press release
announcing the positive recommendation from its safety review
committee to escalate to the second dose level in its camsirubicin
Phase 1b trial in patients with advanced soft tissue
sarcoma.
The
press release is furnished as Exhibit 99.1 to this report and
incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits
Exhibit
No.
|
Description
|
|
Press Release Dated December 8,
2021
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Monopar
Therapeutics Inc.
|
|
|
|
|
|
Date: December 8,
2021
|
By:
|
/s/
Kim R.
Tsuchimoto
|
|
|
|
Name: Kim R.
Tsuchimoto
|
|
|
|
Title: Chief
Financial Officer, Secretary and Treasurer
|
|